Targiniq ER FDA Approval History
FDA Approved: Yes (Discontinued) (First approved July 23, 2014)
Brand name: Targiniq ER
Generic name: naloxone and oxycodone
Dosage form: Extended-Release Tablets
Company: Purdue Pharma LP
Treatment for: Pain
Marketing Status: Discontinued
Targiniq ER (naloxone and oxycodone) is an opioid antagonist and opioid analgesic combination in a long-acting abuse-deterrent formulation for the management of chronic severe pain.
Development timeline for Targiniq ER
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.